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Abstract
Purpose TP53germline (g) mutations, associated with the Li-Fraumeni syndrome (LFS), have rarely been reported in the 
context of hereditary breast and ovarian cancer (HBOC). The prevalence and cancer risks in this target group are unknown 
and counseling remains challenging. Notably an extensive high-risk surveillance program is implemented, which evokes 
substantial psychological discomfort. Emphasizing the lack of consensus about clinical implications, we aim to further 
characterize TP53g mutations in HBOC families.
Methods Next-generation sequencing was conducted on 1876 breast cancer (BC) patients who fulfilled the inclusion criteria 
for HBOC.
Results (Likely) pathogenic variants in TP53 gene were present in 0.6% of the BC cohort with higher occurrence in early 
onset BC < 36 years. (1.1%) and bilateral vs. unilateral BC (1.1% vs. 0.3%). Two out of eleven patients with a (likely) patho-
genic TP53g variant (c.542G > A; c.375G > A) did not comply with classic LFS/Chompret criteria. Albeit located in the 
DNA-binding domain of the p53-protein and therefore revealing no difference to LFS-related variants, they only displayed 
a medium transactivity reduction constituting a retainment of wildtype-like anti-proliferative functionality.
Conclusion Among our cohort of HBOC families, we were able to describe a clinical subgroup, which is distinct from the 
classic LFS-families. Strikingly, two families did not adhere to the LFS criteria, and functional analysis revealed a reduced 
impact on TP53 activity, which may suit to the attenuated phenotype. This is an approach that could be useful in developing 
individualized screening efforts for TP53g mutation carrier in HBOC families. Due to the low incidence, national/interna-
tional cooperation is necessary to further explore clinical implications. This might allow providing directions for clinical 
recommendations in the future.
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Background
Germline (g) mutations in the TP53 gene have rarely been 
reported in the context of hereditary breast and ovarian can-
cer (HBOC). So far, mutations have been associated with 
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the Li- Fraumeni syndrome (LFS), an autosomal dominant 
cancer syndrome caused by a heterozygous germline muta-
tion in the TP53 gene. LFS predisposes to a wide spectrum 
of malignancies including premenopausal breast cancer, soft 
tissue and bone sarcoma, leukemia, brain cancer, bronchoal-
veolar lung cancer, and adrenocortical carcinoma (3). Some 
of the LFS-related cancers already occur during childhood or 
adolescence. For the diagnosis of LFS, the classic Chompret 
criteria must be met (Tables 1, 2) or a germline pathogenic 
variant in TP53 is detected (3). At least 70% of individuals 
who meet the classic LFS criteria and approximately 20% 
of those, who meet the Chompret criteria have an identi-
fiable germline pathogenic variant in TP53 (3). The esti-
mated lifetime risks of developing breast cancer for female 
TP53 mutation carriers is 80–90% compared to 60–85%, 
for female BRCA mutation carriers [1, 2]. Until now, there 
has been no discussion on the recommendation of routine 
genetic testing for a TP53g mutation in families who fulfill 
the inclusion criteria for LFS, as shown in Tables 1, 2. In the 
general population, TP53g mutations are found at a very low 
heterozygous frequency of 0.025% [3]. However, recent data 
has shown that the introduction of next-generation sequenc-
ing has led to a considerably higher prevalence of TP53g 
mutations in the context of HBOC [2, 4].
In regards to clinical management of cancer patients, 
identifying a TP53g mutation is highly relevant when 
selecting a treatment regimen; studies suggest that muta-
tion carriers are particularly sensitive to radiation exposure 
and chemotherapy, resulting in a substantially increased 
prevalence of secondary malignancies [1]. Breast cancer is 
the most commonly diagnosed cancer in TP53 g mutation 
carriers, with risk estimates of 85% by age 60 [2, 3]. Indeed, 
in women diagnosed with breast cancer before age 40, there 
is a notable risk for a TP53g mutation; the prevalence varies 
from < 1 to 7%, whereas the highest risks are estimated for 
women with a breast cancer diagnosis before age 30 years 
[2, 4–7].
Recently, genetic testing for TP53g mutations has become 
more and more prevalent in clinical routine. However, it is 
challenging to counsel TP53g mutation carriers regarding 
the risk of hereditary breast and ovarian cancer. Among oth-
ers, the multigene panel testing often reveals a variant of 
uncertain significance, whose relevance needs to be assessed 
prior to a potential translation into clinical practice. Eluci-
dating possible genotype–phenotype correlations and other 
cancer-predisposing risk factors is inevitable in order to pro-
vide comprehensive genetic counseling.
This study aimed to further characterize the spectrum of 
germline TP53g mutations in a sample of 1876 well-defined 
familial BC/HBOC index patients from Germany who were 
tested negative for a germline BRCA mutation, and report 




In the present study, we examined a cohort of 1876 HBC/
HBOC index patients who were counseled and referred 
for genetic testing at the Department of Gynecology and 
Table 1  classic LFS criteria
Adapted by Mai et al. 2012 [32]
Classic LFS criteria (all criteria must be fulfilled)
1. A sarcoma diagnosed before age 45 years AND
2. A first-degree relative with any cancer diagnosis before age 45 years AND
3. A first- or second-degree relative with any cancer diagnosis before age 45 years or sarcoma at any age
Table 2  Chompret criteria
Adapted by Bougeard et al. 2015 [28]
LFS Li-Fraumeni syndrome
Chompret criteria for LFS
1. Proband diagnosed with a core LFS tumor (soft-tissue sarcoma, osteosarcoma, premenopausal breast cancer, CNS tumor, adrenocortical 
carcinoma) before age 46 years AND at least one first- or second-degree relative with a core LFS tumor (except breast cancer, if the proband 
has breast cancer) before age 56 years
2. OR a proband with multiple primary tumors (except multiple breast cancers), two of which are LFS core tumors, with the first occurring at 
age < 46 years
3. OR a proband with adrenocortical carcinoma, choroid plexus carcinoma, or rhabdomyosarcoma of embryonal anaplastic subtype, irrespective 
of family history
4. OR a proband with breast cancer < 31 years
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Center for Hereditary Breast and Ovarian Cancer, Klinikum 
Rechts der Isar, Technical University of Munich (TUM) and 
Klinikum Großhadern, Ludwigs-Maximilians-University 
of Munich (LMU) between July 2014 and December 2017. 
1464 patients were tested by panel analysis. 412 patients 
who tested negative for a pathogenic BRCA mutation 
respectively and met at least one of the inclusion criteria for 
genetic testing as proposed by the German consortium of 
Hereditary Breast and Ovarian Cancer (GC-HBOC) were 
evaluated by whole-exome sequencing (WES). The inclusion 
criteria are categorized as follows: A: breast cancer at any 
age with two or more close relatives with breast cancer at 
any age; B: breast cancer < 51 years. and at least one relative 
with breast cancer at any age; C: at least one breast cancer 
and one ovarian cancer; D: at least two women with ovarian 
cancer; E: at least one female and one male breast cancer; 
F: at least one ovarian cancer and one male breast cancer; 
G: early onset breast cancer < 36 years.; H: bilateral breast 
cancer (first disease diagnosed > 51 years.); I: a personal his-
tory of breast and ovarian cancer; J: triple-negative breast 
cancer < 50 years.; K: ovarian cancer < 80 years. (Table 3).
Within the counseling, a record of pedigree as well as 
medical report was provided for each patient including the 
age of diagnosis, histological subtype, tumor receptor status, 
tumor stage as well as personal and family history of cancer. 
Written informed consent was obtained from all patients. 
This study is approved by the ethics committee of the Tech-
nical University Munich.
Analysis
Genomic DNA was isolated from blood samples of the 
patients. For 1464 cases, next-generation sequencing and 
data analysis were performed with an Illumina sequencing 
platform, using either the TruSight Cancer Panel (Illumina, 
San Diego, CA, U.S.) or the TruRisk Sequencing Panel 
(Illumina, San Diego, CA, USA). Target enrichment was 
performed using the TruSight Rapid Capture System (Illu-
mina, San Diego, CA, USA). For 412 further cases, exome 
sequencing was performed with the Sure Select system 
for target enrichment (Agilent, Santa Clara, USA) and a 
HiSeq2500 system for sequencing (Illumina, San Diego, 
CA, USA).
All coding exons and adjacent intronic sequences 
(+ /− 20 bp) of the TP53-gene (NM_000546) were analyzed.
The variant classification was performed following the 
regulations of the GC-HBOC [8]. All variants were classified 
using a five-tier classification system (deleterious = class 5, 
likely deleterious = class 4, variant of uncertain significance 
(VUS) = class 3, likely benign = class 2, and benign = class 
1).
For further evaluation, we exclusively focused on class 4 
and 5 variants comprising missense, and essential splice-site 
variants as well as variants of uncertain significance (class 
3) which had previously been verified by Sanger sequencing.
All TP53 variants were proven to be germline by either 
segregation analysis or variant confirmation in correspond-
ing non-cancerous breast tissue.
Statistical comparisons were performed using IBM SPSS 
version 25.
Assessment
For functional assessment, we compared the TP53g vari-
ants according to two well-established published functional 
analysis patterns. First, an alignment with high-resolution 
mutation analysis by Kato et al. was enforced [9]. Stating 
that the sequence-specific transactivation is the critical func-
tion in p53-dependent tumor suppression, the working group 
used a comprehensive site-directed mutagenesis technique 
and a yeast-based functional assay to construct, express, 
and evaluate p53 mutants, and correlated p53 function with 
Table 3  Stratification for subgroups by HBOC inclusion criteria for genetic testing and mutation prevalence
*TP53 mut: including (likely) pathogenic TP53g mutations
HBOC (Hereditary breast and ovarian cancer)-criteria Total TP53 mut* TP53 VUS
n n (%) n  n (% ) n n (%)
a. At least three woman with breast cancer independent of age 90 4.9 – –
b. OR at least two woman with breast cancer, one < 51 years 629 33.5 1 0.2% 14 2.2%
c. OR at least one woman affected by breast and one by ovarian cancer 173 9.2 – –
d. OR at least two woman affected by ovarian cancer 51 2.7 – –
e. OR at least one female and one male breast cancer 23 1.2 – –
f. OR at least one woman affected by ovarian cancer and one man affected by 
breast cancer
2 1.3 – –
g. OR at least one woman affected by breast cancer < 36 years 621 33 7 1.1% 5 0.8%
h. OR at least one woman affected by bilateral breast cancer, first < 51 years 209 11 2 0.9% 1 0.5%
i. OR at least one woman affected by breast and ovarian cancer 78 4 1 1.2% –
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structure- and tumor-derived mutations [9]. Secondly, the 
synthetically designed TP53 library created by Kotler et al. 
[10] was used to detect further coherences. The working 
group measured the functional impact of around 10,000 
DNA-binding domain (DBD) p53 variants in human cells 
in culture and in vivo [10]. In order to allow quantitative 
comparison between variants, they calculated a relative fit-
ness score (RFS) for each variant based on its retention (or 
depletion) and created a trained model that allows to provide 
an accurate estimation of the phenotypic effects of p53 vari-
ants [10]. Based on this model, Kotler et al. [10] suggested a 
RFS >  − 1 for TP53 DBD mutations that compromise anti-
proliferative functionality and correlated a RFS ≤ − 1 to 
TP53g mutations that retain anti-proliferative capacity [10]. 
They also suggest that LFS families with the six most preva-
lent hotspot mutations (R175H, R273H, R248Q, R248W, 
R273C, and R282W) even exhibit a somewhat lower age 
at tumor diagnosis by probably eliciting additional gain-of-
function effects [10].
Results
TP53g mutation prevalence in the context 
of families with hereditary breast and ovarian 
cancer
Our analysis considered a total of 1876 index patients 
who presented with the diagnosis of breast cancer. In 
this cohort, the mean age at breast cancer diagnosis was 
43 years (range 18–77). All corresponding pedigrees were 
conducted into seven mutually exclusive groups of clus-
tered familial cancer histories (Table 3) according to the 
inclusion criteria of the GC-HBOC (Table 3). Overall, 
heterozygous (likely) pathogenic mutations in the TP53 
gene were detected in 11 of the 1876 familial female 
breast cancer index patients, yielding a prevalence rate 
of 0.6% (11/1876). The sequence variants comprised 10 
missense mutations (10/11; 91%) and 1 splice-site muta-
tion (1/11; 9%) (Table 5). The mean age of these TP53g 
mutation carriers at breast cancer diagnosis was 35 years 
(range 22–49 years). Clinical characteristics are sum-
marized in Supplement 1. Eight of the TP53g mutation 
carriers presented with unilateral premenopausal breast 
cancer, whereas three women were diagnosed with bilat-
eral breast cancer. Furthermore, two of the mutation carri-
ers had a history of an adolescent malignancy (colorectal 
cancer 21 years; osteosarcoma 16 years.) in addition to 
their breast cancer disease. When considering the GC-
HBOC inclusion criteria, the highest mutation frequencies 
were seen in families with at least one woman affected by 
breast cancer < 36 years. (1.1%) and families with at least 
one woman affected by breast and ovarian cancer (1.2%) 
(Table 3).
In addition, a total of 20 variants of uncertain sig-
nificance (VUS) were identified in the TP53 gene 
(Tables  3, 6), predicting a prevalence rate of 1.1% in 
the overall patient sample. Most VUS were rare mis-
sense variants (17/20; 85%). Indices carrying a VUS in 
the TP53 gene presented with a mean age of 42.2 years 
(range 28–64 years.) at the time of breast cancer diagno-
sis. Clinical characteristics are provided in Supplement 
2. The majority presented with unilateral breast cancer 
(n = 16), bilateral breast cancer was found in four women 
and there was no malignancy in childhood/adolescence. In 
this group, the highest mutation frequencies were found 
in families with at least two women with breast cancer, 
one < 51 years. (2.2%) (Table 3).
For a more detailed description of mutation frequencies, 
the familial cancer histories were further elaborated. The 
mutation prevalence in families with exclusive diagnosis 
of female breast cancer is shown in Table 4 (97.5% of all 
families). Group A comprises families with the exclusive 
occurrence of unilateral breast cancer (87.4% of all fami-
lies), whereas group B (21.3%) primarily includes cases 
of premenopausal and postmenopausal bilateral breast 
cancer. (Likely) deleterious TP53g mutations and vari-
ants of uncertain significance were much more frequent in 
families with bilateral breast cancer compared to families 
with unilateral breast cancer (TP53g mut: 1.1% vs. 0.3%; 
TP53g-VUS: 1.4% vs. 0.9%, respectively) (Table 4).
Table 4  TP53 mutation prevalence in families with female breast cancer only
bBC bilateral breast cancer disease; mBC male breast cancer disease; OC ovarian cancer; Prev Prevalence
*TP53 mut: including (likely) pathogenic TP53g mutations
Familial cancer history (including proband) Total
N
 % of total TP 53 mut*
N 
Prev % TP53 VUS
N 
Prev %
I. Total cohort 1876 11 0.6% 20 1.1%
II. GROUP A: female unilateral breast cancer 
cases only (bBC, mBC, and OC excluded)
1639 87.4% 5 0.3% 14 0.9%
III. GROUP B: female BC, of these > 1bBC
(mBC and OC excluded)
366 21.3% 4 1.1% 5 1.4%
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Characterization of TP53g variants
Association of TP53g mutations with tumor receptor status
Considering tumor biology, (likely) deleterious mutation 
carriers presented the following distribution at the time of 
the first breast cancer diagnosis: 18% TNBC (n = 2), 36% HR 
pos HER2-neg (n = 4), and 45% HER2-pos (n = 5) (Fig. 1). 
Three out of eleven patients developed contralateral breast 
cancer within a median time of 2 years (range 0–4 years) 
from the first diagnosis. Tumor biology was equally distrib-
uted, exhibiting TNBC, HR pos HER2neg and HER2 pos 
biologies respectively.
Alignment with LFS inclusion criteria
However, since LFS-families are typically categorized 
under the classic LFS/Chompret criteria, we additionally 
assigned the according pedigrees to these criteria. Inter-
estingly, two of eleven patients with breast cancer disease 
had a (likely) pathogenic TP53g missense mutation and 
did not fulfill the LFS/Chompret criteria (18%) (Supple-
ment 1). The corresponding pedigrees are shown in Fig. 2. 
The first patient carried a likely deleterious de novo TP53g 
variant (NM_000546.5:c.375G > A (p.Thr125Thr)) and pre-
sented with a bilateral breast cancer at the age of 39 years. 
(Fig. 2 pedigree #1). The corresponding synonym variant is 
attributed to cause aberrant splicing [11–13] and has been 
reported in several LFS-families [12–18].
In another patient, the likely deleterious TP53g mutation 
(NM_000546.5:c.542G > A (p.Arg181His)) was detected, 
which has been shown to be associated with breast cancer in 
the literature, glioblastoma multiforme, and adrenocortical 
carcinoma in few individuals. However, a late manifesta-
tion of cancer disease (> 50 years.) was stated for all these 
patients, and functional analyses demonstrated mixed results 
regarding DNA binding, transactivation and growth suppres-
sion [10, 19–21]. Our patient was diagnosed with breast can-
cer at the age of 46 years, her mother at the age of 41 years 
(Fig. 2, pedigree #2). The mutation was confirmed to be 
germline by testing non-cancerous breast tissue of the index.
Phenotype/genotype correlation by functional 
analysis
All (likely) deleterious mutations in this cohort are found 
to be located at the DNA-binding domain (DBD). Thus, no 
difference in DNA localization could be determined between 
corresponding pedigrees that fulfilled the classic LFS /
Chompret criteria and those who only fulfilled the HBOC 
inclusion criteria.
For information on functional analysis, the transactivity 
level derived from the high-resolution mutation analysis by 
Kato et al. [9] could be obtained for nine of eleven (likely) 
deleterious TP53g mutations. The level of transactivity 
was strongly/ very strongly reduced in seven of these TP53 
mutations. One likely deleterious TP53g mutation revealed 
a moderate strong reduction (NM_00546.5:c.717c > G 
(p.Asn239Lys)) and only one likely deleterious TP53g muta-
tion (NM_000546.5:c.542G > A (p.Arg181His)) showed a 
medium reduction of transactivity. This family did not meet 
the inclusion criteria for classic LFS (Fig. 2, pedigree #2).
Tumors in childhood and early adulthood were exclu-
sively detected if p53 functionality was very strongly 
reduced. The same applied to family history.
The functional model by Kotler et al. [10] was applied 
to investigate for further coherences. We found seven of ten 
(likely) deleterious mutations of our cohort (missing data: 
n = 1) to reveal a relative fitness score of > − 1, implicating 
a loss of proliferative functionality (Table 5) that was con-
sistent with phenotypic characteristics. The corresponding 
pedigrees fulfilled not only the HBOC inclusion criteria but 
also the Chompret inclusion criteria. Interestingly, for pedi-
gree 1 and 2, Kotler et al. [10] calculated a RFS ≤  − 1, which 
implies a retaining wtp53-like-anti-proliferative functional-
ity and therefore explains the attenuated phenotype (Fig. 2).
Variants of uncertain significance
In a second step, we performed the same analysis for all 20 
VUS, which occurred in our cohort, and categorized accord-
ing to their localization on DNA (Table 6). Additionally, we 
correlated the VUS according to the transactivity reduction 












TNBC HR+ HER2neu - HER2neu +
Fig. 1  Distribution of tumor biology in (likely) deleterious TP53g 
mutations. The Figure depicts the phenotype of the tumors in this 
study, which was associated with a deleterious/likely deleterious 
TP53 mutation. TNBC triple-negative BC, HR + HER2neu- hormone 
receptor-positive HER2neu non-amplified, HER2neu +  HER2neu 
amplified
1562 Archives of Gynecology and Obstetrics (2021) 303:1557–1567
1 3
must be pointed out that Kotler et al. restricted their analysis 
to DBD variants [10] whereas only 9 out of 20 VUS detected 
in our cohort, were localized on the DNA-binding domain. 
Yet no difference could be identified concerning the distinct 
behavior of breast cancer manifestation.
Discussion
In this study we describe TP53g mutations in the context of 
families with hereditary breast and ovarian cancer. (Likely) 
pathogenic variants in TP53 gene were present in 0.6% 
of the cohort. This is in line with previous studies, which 
describe a low TP53g mutation prevalence among women, 
who have had breast cancer panel testing [22–25].
For classic Li-Fraumeni families, a profound high-risk 
surveillance program has been implemented including a 
full-body magnetic resonance imaging (MRI) scan to be 
conducted annually beginning at early age (Table 7) [26, 
27]. The examinations are associated with enormous psy-
chological and physiological stress and discomfort, which 
raises the question if a more individualized surveillance may 
be more acceptable for families with hereditary breast and 
ovarian cancer without additional features indicative of LFS.
Taking the GC-HBOC inclusion criteria into considera-
tion, one of the highest mutation frequencies of (likely) del-
eterious TP53g mutations was seen in families with early 
onset of breast cancer (< 36 years. (1.1%)) (Table 3). How-
ever, the mutation prevalence in this subgroup was lower 
than most studies previously reported, which were largely 
Fig. 2  Pedigree#1 and #2 
emphasize individuals with 
a pathogenic TP53 germline 
mutation that lack classic per-
sonal or family history of LFS-
related cancers and do not fulfill 
TP53 testing criteria. Pedigree 
#1: Pedigree #1 displays a likely 
deleterious de novo TP53 vari-
ant (NM_000546.5:c.375G > A 
(p.Thr125Thr)). The indi-
vidual presented with a bilateral 
breast cancer disease at the 
age of 39 years. Pedigree 
#2: In pedigree #2 a likely 
deleterious TP53 mutation 
(NM_000546.5:c.542G > A 
(p.Arg181His),) was detected, 
which was associated with the 
late manifestation of cancer 
disease. The index patient was 
diagnosed with breast cancer 
disease at the age of 46 years 
and her mother at the age of 
41 years respectively
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limited by a smaller sample size [4–7, 28, 29] (Table 8). Yet, 
similar results were recently demonstrated in a nationwide 
cohort study from the Netherlands. Their analysis revealed 
a prevalence rate of 2.2% among early onset breast cancer 
BRCA1/BRCA2 mutation negative patients, unselected for 
family history and 0.9% if there were no additional features 
indicative of LFS [30].
Even though our analysis additionally revealed a preva-
lence rate of 1.2% in families with breast and ovarian cancer, 
it should be noted that the cohort is underrepresented (n = 1) 
and therefore does not allow drawing conclusions about the 
impact of a (likely) deleterious TP53g mutation on ovarian 
cancer. According to literature, genetic predisposition for 
ovarian cancer is still highly controversial.
When considering families with the exclusive occurrence 
of female breast cancer, the analysis revealed that (likely) 
deleterious TP53g mutations as well as variants of uncer-
tain significance were much more frequent in families with 
bilateral compared to families with unilateral breast can-
cer (TP53mut: 1.1% vs. 0.3%; TP53-VUS: 1.4% vs. 0.9%) 
(Table 4).
Aiming to advance our understanding regarding possi-
ble correlations between cancer risks and characteristics 
depending on the type of TP53g mutation, we assigned all 
TP53g variants (n  = 31: (likely) pathogenic variants and 
VUS) accordingly to the DNA localization.
As presumed, variants in the DNA-binding domain 
tended to correlate with early onset of breast cancer as well 
as early development of contralateral breast cancer. In par-
ticular tumor development in childhood/early adulthood 
was exclusively associated with TP53g alterations located 
on the binding domain. To further categorize the impact of 
these TP53g variants, we enforced an alignment with high-
resolution mutation analysis by Kato et al. [9] as well as 
relative fitness score by Kotler et al. [10]. TP53g-variants 
displaying strong and very strong transactivity reductions 
and RFS >  − 1 were predominately associated with early 
onset malignancies (except breast cancer). Whether personal 
or family history, malignancies in childhood/early adult-
hood solely presented if p53 functionality was very strongly 
reduced and a relative fitness score of > − 1 was given.
Interestingly, scoping the two pedigrees with a (likely) 
deleterious TP53g mutation that only fulfilled the HBOC cri-
teria, the corresponding TP53 mutations were located on the 
core DNA-binding domain. Yet, we gained decisive knowl-
edge when considering information on functional analysis. 
First, we aimed to elucidate the transactivity function of p53 
[9]. Even though transactivity data was missing for pedi-
gree 1 (c.375G > A (p.Thr125Th)) (Fig. 2, pedigree #1)), 
the likely deleterious variant c.542G > A (p.Arg181His) of 
pedigree 2 was associated with a medium reduction in p53 
activity (Fig. 2, pedigree #2)). Furthermore when comparing 
Table 5  Functional data- 
(likely) deleterious mutations in 
the TP53 gene
RFS ≤ − 1: retaining wtp53-like anti-proliferative functionality
RFS > − 1: disrupting functionality
Hotspot mutations: R175H, R273H, R248Q, R248W, R273C, R282W
**RTS (relative fitness score)
Genomic position Protein change DNA domain Transcriptional activity in 
yeast (% of wild-type)
Relative fitness 
score (RFS)**
c.375G > A p.Thr125Thr DNA-binding domain Unknown RFS ≤ − 1
c.542G > A Arg181His DNA-binding domain Medium reduction
(50.3%)
RFS ≤ − 1
c.700 T > C Tyr234His DNA-binding domain Very strong reduction
(0.89%)
RFS > − 1
c.717C > G Asn239Lys DNA-binding domain Moderate strong reduction
(26.4%)
RFS < −1
c.733G > A Gly245Ser DNA-binding domain Strong reduction
(4.2%)
RFS > − 1
c.742C > T Arg248Trp DNA-binding domain Very strong reduction
(0.09%)
RFS > − 1
c.743G > A p.Arg248Gln DNA-binding domain Very strong reduction
(0.21%)
RFS > − 1
c.783-2A > G
splice acceptor
p.? DNA-binding domain Unknown Unknown
c.800G > C p.Arg267 Pro DNA-binding domain Very strong reduction
(0.46%)
RFS > − 1
c.817C > T p.273Arg > Cys DNA-binding domain Very strong reduction
(0.76%)
RFS > − 1
c.818G > A Arg273His DNA-binding domain Strong reduction (2.51%) RFS > − 1
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pedigree 1 and 2 (Fig. 2, pedigree #1,2) to the functional 
impact analysis by Kotler et al. [10], we found a RFS ≤  − 1 
for both pedigrees, which constitutes a retainment of wtp53-
like-anti-proliferative functionality. We hypothesize that this 
reduced impact on TP53 functionality may contribute to the 
attenuated phenotype.
Yet, as already mentioned, these mutations have also been 
reported in several individuals meeting either classic Li-
Fraumeni or Chompret criteria. This disparate manifestation 
might additionally imply a co-occurrence of other genetic 
and epigenetic modifiers, which attenuates or enhances the 
effect of decreased p53 anti-proliferative functionality.
Within the current guidelines of the European Reference 
Network GENTURIS, Freybourg et al. argue for a pheno-
typic variability, which strongly endorses the existence of 
genetic and environmental modifying factors [31].
Our findings indicate it is crucial to define subgroups, 
such as breast cancer families, as shown in this work, in 
order to possibly individualize surveillance programs in the 
future.
In this study, we further intended to analyze differences 
between (likely) deleterious mutations and VUS in TP53, 
especially concerning the clinical manifestation.
There is a current lack of knowledge regarding VUS, 
especially when they are located outside of the core DNA-
binding domain. In general, it remains to be seen to what 
extend variants of uncertain significance will be assigned 
to a similar functional restriction as it is already proven for 
known (likely) pathogenic TP53g gene mutations, espe-
cially those with a strong reduction in transactivity func-
tion or rather RFS >  − 1, e.g. the TP53 variant c.470 T > G, 
p.Val157Gly found in our collective. Even if variants are 
classified as VUS at present, they are within an exten-
sive process of dynamic change. To ensure a sustainable 
improvement in reclassification and focusing an enhance-
ment of patient care, GC-HBOC has established a group of 
experts (VUS-task force) who reevaluate these variants of 
uncertain significance.
It is essential to collect data centrally and constantly reas-
sess the existing evidence, in order to advance patient care 
in the long term.
However, our study needs to be interpreted in light of its 
limitations regarding a small number of TP53g mutation 
carriers. Therefore, our current analysis must be consid-
ered as a hypothesis-generating study. Further data are 
necessary to confirm these findings. Additionally, we need 
Table 6  Functional data- variants of uncertain significance in TP53 gene
RFS ≤ − 1: retaining wtp53-like anti-proliferative functionality
RFS > − 1: disrupting functionality
Hotspot mutations: R175H, R273H, R248Q, R248W, R273C, R282W
**RTS (relative fitness score)




c.26G > A p.Ser9Asn Transactivation domain 1 (26.01%) Unknown
c.29 T > G p.Val10Gly Transactivation domain 1 (98.91%) Unknown
c.217G > A p.Val73Met Transactivation domain 2 (93.8%) Unknown
c.255 T > C p.Pro85Pro Transactivation domain 2 Unknown Unknown
c.266C > A p.Pro89His Transactivation domain 2 (5.96%) Unknown
c.333G > T p.Leu111Leu DNA-binding domain Unknown RFS ≤ − 1
c.375 + 6 T > C DNA-binding domain Unknown Unknown
c.457C > T p.Pro153Ser DNA-binding domain (83.55%) RFS ≤ − 1
c.470 T > G p.Val157Gly DNA-binding domain (9.2%) RFS > − 1
c.523C > T p.Arg175 Cys DNA-binding domain (84.36%) RFS ≤ − 1
c.529_546del p.Pro177_Cys182del DNA-binding domain Unknown Unknown
c.572-574del p.Pro191del DNA-binding domain Unknown Unknown
c.663G > A p.Glu221Glu DNA-binding domain Unknown RFS ≤ − 1
c.847C > T p.Arg283Cys DNA-binding domain (85.49%) RFS ≤ − 1
c.927C > T p.Pro309 Pro Nuclear localization domain Unknown Unknown
c.1014 C > T p.Phe338Phe Tetramerization domain Unknown Unknown
c.1014 C > T p.Phe338Phe Tetramerization domain Unknown Unknown
c.1079G > C p.Gly360Ala (78.04%) Unknown
c.1163A > C p.Gln388Ala Regulatory domain (112%) Unknown
c.1171G > A p.Asp391Asn Regulatory domain (94.24%) Unknown
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Table 7  Recommended LFS screening protocol (based on the Toronto protocol)
Adapted by Villani et al. [26, 27, 33]
Large scale surveillance protocol (based on the Toronto protocol) is recommended for individuals with a pathogenic TP53 germline mutation, 
which is associated with enormously psychological discomfort. However the wide adoption of next-generation sequencing (NGS) panels has led 
to a considerably higher prevalence of TP53 mutations in the context of hereditary breast and ovarian cancer, whereof many individuals with 
TP53 mutations lack classic personal or family history of LFS-related cancers. The clinical challenge is to define a subgroup of TP53-mutation 
carriers for whom the screening recommendation should differentiate from the classic LFS-families
MRI magnetic resonance imaging, US ultrasound
Children (birth to 18 years)
 General assessment Complete physical examination and blood tests every 3–4 months
(blood-test: * 17-OH-progesterone, total testosterone, dehydroepiandrosterone sulfate, Androstenedione, 
complete blood count, erythrocyte sedimentation rate, lactate dehydrogenase; 24h urine cortisol, if feasi-
ble)
 Brain tumor Annual brain MRI (first MRI with contrast; thereafter without contrast if previous MRI normal and no new 
abnormality)
 Soft tissue and bone sarcoma Annual whole body MRI
 Adrenocortical carcinoma US of abdomen and pelvis every 3–4 months
Adults
 General assessment Complete physical examination and blood tests every 3–4 months
(blood-test: * 17-OH-progesterone, total testosterone, dehydroepiandrosterone sulfate, Androstenedione, 
complete blood count, erythrocyte sedimentation rate, lactate dehydrogenase; 24h urine cortisol, if feasi-
ble)
 Breast cancer
 (age 18 years onward)
Breast awareness (age 18 years onward)
Clinical breast examination twice a year (age 20 years onward)
Semi-annual breast sonography (age 20 years onward)
Annual breast MRI screening (ages 20–75)
Consider risk-reducing bilateral mastectomy
 Soft tissue and bone sarcoma
 (age 18 years onward)
Annual whole body MRI
US of abdomen and pelvis every 3–4 months
 Brain tumor
 (age 18 years onward)
Annual brain MRI (first MRI with contrast; thereafter without contrast if previous MRI normal)
 Gastrointestinal cancer
 (age 25 years onward)
Upper endoscopy and colonoscopy every 2–5 years
 Melanoma
 (age 18 years onward)
Annual dermatologic examination
Table 8  TP53 germline mutation prevalence among early onset breast cancer patients, tested negative for a BRCA1/2 germline mutation
Adopted by Bakhuizen et al. [30]
*Population based cohort
**Subgroup of total study population
Study Subject N Family history/personal history of multiple LFS-related 
tumors
TP53 prevalance (%)
Lalloo et al. [4] Breast cancer < 31 years* 82** Unselected 4.9% (4/82)
Ginsburg et al. [29] Breast cancer < 30 years 95 Unselected 0% (0/95)
Mouchawar et al. [5] Breast cancer < 30 years* 43** Unselected 4.7% (2/43)
Gonzalez et al. [6] Breast cancer < 30 years 14 No cancer in first/second degree relatives 7.1% (1/14)
McCuaig et al. [7] Breast cancer < 31 years 13 Did not meet classic LFS, LFL or Chompret
2009 criteria
7.7% (1/13)
Bougeard et al. [28] Breast cancer < 30 years Not reported Did not meet Chompret 2009 criteria 6% (not reported)
Bakhuizen et al. [30] Breast cancer < 30 years 233** No sarcoma, brain tumor or ACC in family history; no 
second LFS-related tumor (other than breast cancer)
0.9% (2/233)
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to gain more knowledge about genetic and non-genetic 
modifiers that influence p53 function.
Within the GC-HBOC, we intend to examine TP53g 
mutations in a larger cohort of HBOC families nationwide. 
However due to the low incidence of TP53g mutations, a 
systematic international collaboration is becoming highly 
desirable to focus on this issue and define subgroups of 
TP53g-mutations in non-suggestive clinical situations.
Agreeing on existing evidence and current guidelines 
published by the European Reference Network GEN-
TURIS [31] and based of a lack of consensus, the estab-
lished surveillance program should currently be recom-
mended to all carriers of a (likely) deleterious TP53g 
mutation irrespective of the pedigree.
Conclusion
In this study we were able to define a clinical subgroup 
among our cohort of HBOC families, which phenotypi-
cally differentiates from the characteristic LFS-families. 
By applying a classification following functional data like 
transactivity reduction level [9] as well as relative fitness 
score [10], we determined discrepancies of TP53 func-
tionality that suited the attenuated phenotype. This is an 
approach that could be useful in developing individual-
ized screening efforts for TP53g mutation carrier in HBOC 
families. Due to the low incidence of TP53g mutations, it 
is essential to heighten the perception on this topic and 
provide conditions for national/international collabora-
tions. This might help providing directions for clinical 
recommendations in the future.
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